Page 101 - Essential Haematology
P. 101

Chapter 6  Haemolytic anaemias  /  87


                      factor (DAF, CD55) and membrane inhibitor of  immunologically mediated, against cells that have
                      reactive lysis (MIRL, CD59) render red cells sensi-  normal GPI - linked membrane proteins.

                      tive to lysis by complement and the result is chronic     PNH is diagnosed by flow cytometry which
                      intravascular haemolysis. Haemosiderinuria is a  shows loss of expression of the GPI - linked proteins,
                      constant feature and can give rise to iron defi ciency  CD55 and CD59. Alternatively, a test for loss
                      which may exacerbate the anaemia. CD55 and  of the GPI anchor on  WBC (FLAER) may be
                      CD59 are also present on white cells and platelets.  used.
                      The other main clinical problem seen in PNH is    Eculizumab, a humanized antibody against

                      thrombosis and patients may develop recurrent  complement C5, inhibits the activation of terminal
                      thromboses of large veins including portal and  components of complement and reduces haemoly-
                      hepatic veins, as well as intermittent abdominal  sis and transfusion requirements. Iron therapy

                      pain brought about by thrombosis of mesenteric  is used for iron deficiency and long - term anti-
                      veins.                                    coagulation with warfarin may be needed.
                          PNH is almost invariably associated with some  Immunosuppression can be useful and allogeneic
                      form of bone marrow hypoplasia, often frank aplas-  stem cell transplantation is a defi nitive treatment.
                      tic anaemia. It appears that the PNH clone may  The disease occasionally remits and the median sur-

                      expand as a result of a selective pressure, possibly  vival is approximately 10 years.





                                  ■   Haemolytic anaemia is caused by   transfusion), there is haemoglobinaemia,

                           shortening of the red cell life. The red cells   methaemalbuminaemia, haemoglobinuria
                           may break down in the reticuloendothelial   and haemosiderinuria.
                           system (extravascular) or in the circulation         ■    Genetic defects include those of the red   SUMMARY


                           (intravascular).                        cell membrane (e.g. hereditary
                              ■    Haemolytic anaemia may be caused by   spherocytosis), enzyme defi ciencies (e.g.


                           inherited red cell defects, which are usually   glucose - 6 - phosphate dehydrogenase or
                           intrinsic to the red cell, or to acquired   pyruvate kinase defi ciency) or
                           causes, which are usually caused by an   haemoglobin defects (e.g. sickle cell
                           abnormality of the red cell environment.    anaemia).




                              ■    Features of extravascular haemolysis         ■    Acquired causes of haemolytic anaemia
                           include jaundice, gallstones and        include warm or cold, auto -  or allo -
                           splenomegaly with raised reticulocytes,     antibodies to red cells, red cell
                           unconjugated bilirubin and absent       fragmentation syndromes, infections, toxins
                           haptoglobins. In intravascular haemolysis   and paroxysmal nocturnal
                           (e.g. caused by ABO mismatched blood    haemoglobinuria.




                                        Now visit  www.wiley.com/go/essentialhaematology
                                  to test yourself on this chapter.
   96   97   98   99   100   101   102   103   104   105   106